NCT03449524 (PAH) is a Phase 2 clinical trial of 75mg CXA-10 in PAH, sponsored by Complexa, Inc..

Who is sponsoring NCT03449524?

NCT03449524 is sponsored by Complexa, Inc..

What drugs are being tested in NCT03449524?

Interventions in NCT03449524: 75mg CXA-10, 150mg CXA-10, Placebo.

Is NCT03449524 still recruiting?

NCT03449524 is currently terminated. Last updated 10 August 2020.

Last reviewed 2020-08-10 · How we verify

NCT03449524: PAH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)

Terminated Phase 2 Last updated 10 August 2020

What this trial tests

Phase 2 trial testing 75mg CXA-10 in PAH in 69 participants. Terminated before completion.

Timeline

1 August 2018

Primary endpoint
5 August 2020

5 August 2020

Quick facts

Lead sponsor	Complexa, Inc.
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	69
Start date	1 August 2018
Primary completion	5 August 2020
Estimated completion	5 August 2020
Sites	46 locations across United Kingdom, United States

Drugs / interventions tested

75mg CXA-10 — full drug profile →
150mg CXA-10 — full drug profile →
Placebo

Conditions studied

PAH — all drugs for PAH →

Sponsor

Complexa, Inc. — full company profile →

Who can join

Adults 18 to 80, any sex, with PAH. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter double-blind, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of 2 doses of CXA-10 on stable background therapy in 96 subjects 18 to 80 years of age with PAH.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Complexa, Inc. trials

Trials by the same sponsor.

NCT04053543 — CXA-10 Study in Subjects With Pulmonary Arterial Hypertension · Phase 2 · terminated
NCT03422510 — FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS) · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03449524 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Complexa, Inc.
Last refreshed: 10 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03449524.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing